Ndong C, et al., 10:2595-617, Int J Nanomedicine , 2015
This article demonstrates molecular targeting of Iron oxide nanoparticles (IONPs) to the folate receptor alpha (FOLRα) biomarker for cancer by using an engineered antibody fragment (Ffab). The IONPs used in this study were functionalized with the fab fragment of a humanized antibody called Farletuzumab. A series of in vitro as well as in vivo assays were used for the characterization. In addition to ELISA, an Octet RED system equipped with Streptavidin Biosensor probes was used to obtain affinity measurements for Ffab. Varying concentrations of rFOLR1-his were used in a 96-well plate as analyte solutions.